Jefferies Financial Group assumed coverage on shares of Allena Pharmaceuticals (NASDAQ:ALNA) in a research note released on Thursday morning. The firm issued a buy rating and a $22.00 target price on the stock.
Several other equities research analysts have also weighed in on ALNA. B. Riley upped their price objective on Allena Pharmaceuticals from $23.50 to $25.00 and gave the company a buy rating in a research note on Wednesday, August 8th. Zacks Investment Research lowered Allena Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, October 9th. Wedbush reiterated a buy rating and issued a $38.00 price objective on shares of Allena Pharmaceuticals in a research note on Tuesday, October 23rd. LADENBURG THALM/SH SH began coverage on Allena Pharmaceuticals in a research note on Thursday, August 2nd. They issued a buy rating and a $23.00 price objective on the stock. Finally, Cowen reiterated a buy rating on shares of Allena Pharmaceuticals in a research note on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $29.14.
ALNA traded down $0.50 on Thursday, hitting $8.11. 10,900 shares of the stock traded hands, compared to its average volume of 84,740. Allena Pharmaceuticals has a 52 week low of $6.13 and a 52 week high of $17.56. The company has a quick ratio of 29.32, a current ratio of 29.32 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $159.38 million and a price-to-earnings ratio of -1.69.
Allena Pharmaceuticals (NASDAQ:ALNA) last issued its quarterly earnings results on Wednesday, November 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.01. Equities research analysts expect that Allena Pharmaceuticals will post -1.76 EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in ALNA. Wells Fargo & Company MN grew its stake in shares of Allena Pharmaceuticals by 246.4% in the 1st quarter. Wells Fargo & Company MN now owns 9,336 shares of the company’s stock valued at $103,000 after purchasing an additional 6,641 shares during the period. BlackRock Inc. grew its stake in shares of Allena Pharmaceuticals by 2.2% in the 1st quarter. BlackRock Inc. now owns 231,654 shares of the company’s stock valued at $2,553,000 after purchasing an additional 4,879 shares during the period. Millennium Management LLC boosted its holdings in shares of Allena Pharmaceuticals by 311.9% in the 1st quarter. Millennium Management LLC now owns 92,079 shares of the company’s stock worth $1,015,000 after acquiring an additional 69,723 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Allena Pharmaceuticals in the 2nd quarter worth approximately $242,000. Finally, Alps Advisors Inc. acquired a new position in shares of Allena Pharmaceuticals in the 2nd quarter worth approximately $391,000. Institutional investors own 84.93% of the company’s stock.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.